Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tiotropium bromide. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Common Drug Review. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that tiotropium bromide (Spiriva Respimat) be listed for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for the reduction of exacerbations, if the following condition is met: List in a manner similar to Spiriva HandiHaler. Indexing Status Subject indexing assigned by CRD MeSH Humans; Pulmonary Disease, Chronic Obstructive Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32016000153 Date abstract record published 28/01/2016 |